Effects of artemisinin on proliferation and apoptosis of human liver cancer HepG2 cells: A protocol of systematic review and meta-analysis.


Journal

Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R

Informations de publication

Date de publication:
May 2020
Historique:
entrez: 24 5 2020
pubmed: 24 5 2020
medline: 17 6 2020
Statut: ppublish

Résumé

This study will examine the effects of artemisinin on proliferation and apoptosis of human liver cancer HepG2 cells (HLCHG-2C). This study will systematically retrieve potential literatures in MEDLINE, Scopus, Web of Science, Cochrane Library, EMBASE, WANGFANG, and China National Knowledge Infrastructure from their initiation to the February 29, 2020. There are not limitations related to the language and publication time. All case-controlled studies (CCSs) or randomized controlled studies (RCSs) will be included in this study which investigated the effects of artemisinin on proliferation and apoptosis of HLCHG-2C. Two independent investigators will examine searched records, collect data from included studies, and will identify their methodological quality. Any divergences will be disentangled by discussion with another investigator. RevMan 5.3 software will be placed to pool the data and to carry out data analysis. This study will summarize all eligible studies to test the effects of artemisinin on proliferation and apoptosis of HLCHG-2C. The results of this study will exert evidence to examine the effects of artemisinin on proliferation and apoptosis of HLCHG-2C, and it may benefit further research, patients, and healthcare providers. INPLASY202040075.

Sections du résumé

BACKGROUND BACKGROUND
This study will examine the effects of artemisinin on proliferation and apoptosis of human liver cancer HepG2 cells (HLCHG-2C).
METHODS METHODS
This study will systematically retrieve potential literatures in MEDLINE, Scopus, Web of Science, Cochrane Library, EMBASE, WANGFANG, and China National Knowledge Infrastructure from their initiation to the February 29, 2020. There are not limitations related to the language and publication time. All case-controlled studies (CCSs) or randomized controlled studies (RCSs) will be included in this study which investigated the effects of artemisinin on proliferation and apoptosis of HLCHG-2C. Two independent investigators will examine searched records, collect data from included studies, and will identify their methodological quality. Any divergences will be disentangled by discussion with another investigator. RevMan 5.3 software will be placed to pool the data and to carry out data analysis.
RESULTS RESULTS
This study will summarize all eligible studies to test the effects of artemisinin on proliferation and apoptosis of HLCHG-2C.
CONCLUSION CONCLUSIONS
The results of this study will exert evidence to examine the effects of artemisinin on proliferation and apoptosis of HLCHG-2C, and it may benefit further research, patients, and healthcare providers.
SYSTEMATIC REVIEW REGISTRATION BACKGROUND
INPLASY202040075.

Identifiants

pubmed: 32443376
doi: 10.1097/MD.0000000000020290
pii: 00005792-202005150-00092
pmc: PMC7254480
doi:

Substances chimiques

Anti-Infective Agents 0
Artemisinins 0
artemisinin 9RMU91N5K2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e20290

Références

Curr Epidemiol Rep. 2019 Jun;6(2):104-111
pubmed: 31259140
Biomed Res Int. 2019 Jun 25;2019:4696843
pubmed: 31341898
Zhonghua Gan Zang Bing Za Zhi. 2020 Feb 20;28(2):112-128
pubmed: 32164061
PLoS One. 2017 Oct 26;12(10):e0186699
pubmed: 29073275
Hepatol Int. 2017 Jul;11(4):317-370
pubmed: 28620797
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Hepatol Res. 2020 Jan;50(1):15-46
pubmed: 31655492
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Cancer Med. 2019 Sep;8(12):5787-5799
pubmed: 31385465
JAMA Oncol. 2018 May 1;4(5):661-669
pubmed: 29543938
Br J Surg. 2017 Dec;104(13):1775-1784
pubmed: 29091283
Cell Physiol Biochem. 2017;41(2):609-622
pubmed: 28214839
Asian Pac J Cancer Prev. 2014;15(10):4307-9
pubmed: 24935389
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
Medicine (Baltimore). 2019 Nov;98(44):e17552
pubmed: 31689758
PLoS One. 2019 Aug 14;14(8):e0221079
pubmed: 31412075
Anticancer Res. 2020 Apr;40(4):2089-2093
pubmed: 32234901

Auteurs

Jing Li (J)

Department of Physiology, Jiamusi University School of Basic Medical Sciences.

Zhi-Ye Liu (ZY)

Department of Chemotherapy and Radiotherapy, First Affiliated Hospital of Jiamusi University.

Hai-Bo Yu (HB)

Department of Cardiology, First Affiliated Hospital of Jiamusi University.

Qing Xue (Q)

Clinical Medicine of Class 7 in Grade 2016, Jiamusi University, Jiamusi, 154002, China.

Xiu-Sheng Qu (XS)

Department of Chemotherapy and Radiotherapy, First Affiliated Hospital of Jiamusi University.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH